Loading…
Loading…
Should we expect the data this year? And do you want to give us any color on the reliability of the Phase II into the Phase III, just given it's a tough condition?
Any sense sort of -- is this going to be in a medical meeting? And can you give us any sense kind of what to really expect and put it in context?
In Q4, when we have the second year data, how much granularity are we going to be able to glean from the patients who are going on maintenance?
at ADA, is there a chance to get maybe even the 76-week data, from the obesity study from the Phase II, including some of the less frequent dose
On 514, the one that's on clinical hold for obesity, can you comment, was that an incretin or non-incretin mechanism?
AMGEVITA was extremely strong at 294. Is that sustainable from now on? What drove that?